NCT06093841View on ClinicalTrials.gov

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

January 21, 2024

Study Completion Date

November 4, 2029

Conditions
Lymphoma, Large B-Cell, DiffuseFollicular Lymphoma Grade 3BHigh-grade B-cell LymphomaMediastinal B-Cell Diffuse Large Cell Lymphoma
Interventions
BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (13)

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,, Shanghai

215006

The First Affiliated Hospital of Soochow University, Suzhou

300000

Institute of Hematology&Hospital of Blood Disease CAMS, Tianjin

Unknown

Sun Yat-sen University Cancer Hospital, Guangzhou

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Hunan Cancer Hospital, Changsha

Shandong Cancer Hospital, Jinan

Tianjin Cancer Hospital, Tianjin

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Beijing Tongren Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY